You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Topic 380- QIDS: Using Radiomics to Impact Radiotherapy Treatment Planning- Moonshot

    SBC: HealthMyne, Inc.            Topic: NCI

    HealthMyne proposes developing a Clinical Decision Support tool to be used in the point-of-care workflow for the Radiation Oncologist that uses radiomic features that have evidence-based association to disease course and/or normal organ damage, in order to impact the treatment planning process. Phase 1 will focus on extraction, calculation, and validation of identified radiomic features for lung c ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Computerized Screening for Comorbidity in Adolescents with Substance or Psychiatric Disorders

    SBC: KOBAK, KENNETH A            Topic: 104

    Project Summary This is a supplementalrenewalgrant to the Phase II SBIR grantComputerized Screening for Comorbidity in Adolescents with Substance or Psychiatric DisordersSince the funding of the Phase I granttwo significant developments occurred in the fieldthe American Psychiatric Association s release of the DSMmanualand NIMH s launch of the Research Domain CriteriaRDoCinitiative that aims to cr ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a cell based assay to assess antigen specific tolerance

    SBC: SALUS DISCOVERY LLC            Topic: R

    Project Summary Despite advances in the field of transplantation that have curbed acute rejection through immunosuppressive drugs and better control of infection and ischemia reperfusion injurychronic allograft rejection is still a major obstacle for successful organ transplantationSuccessful organ transplantation appears to require a balanced function of effector and regulatory T cellsTregto prev ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine

    SBC: STEM PHARM, INCORPORATED            Topic: 106

    Project Summary Abstract Human neural cells manufactured using patient derived induced pluripotent stem cellsiPSCshold great promise for modeling neurodevelopmental disordersdiscovering new precision therapiesand screening for potential risks from environmental toxinsHoweverbiomanufacturing of neural cells and tissues is severely limited by low efficiencypoor reproducibilityand extended timeframes ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    Seasonal influenzafluvirusan NIAID category C priority pathogencauses widespread infectionresulting in at leastmillion cases of severe illness anddeaths worldwideWhile annual vaccination is recommended for all individuals aged overmonths in the UScurrent vaccines are only aroundeffective and there is an urgent need for safemore effective influenza vaccines that offer broad spectrum protectionTo me ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. RAPID: An Extremely Fast Monte Carlo Dose Computing Software for Nuclear Medicine

    SBC: VOXIMETRY INC            Topic: 100

    PROJECT SUMMARY and ABSTRACT The clinical outcome of radiation therapy depends on delivering the highest possible absorbed dose to the tumor swhile limiting the dose to normal tissuesUnfortunatelyunlike external beam radiotherapyEBRTcurrent RT prescription methods do not consider absorbed dose to individual patients but instead use empirically derived or standard methodsThusup toof these patients ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Myeloperoxidase Inhibitor for Treating Multiple Sclerosis

    SBC: ReNeuroGen LLC            Topic: 102

    Abstract Multiple sclerosisMSis an inflammatory demyelinating disease of the central nervous systemCNSIt is the most common autoimmune disease affecting the CNSAlthough much attention has focused on the immunological mechanisms in MSnew evidence suggests that oxidative stress also induces MS neuropathologyMyeloperoxidaseMPOis a powerful peroxidative enzyme that has long been considered a therapeut ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Selection and Development of a Lead Biologic for Treating Mitochondrial Disorders

    SBC: CYTEGEN CORP            Topic: NIA

    Project Summary Abstract Mitochondrial dysfunction causes mitochondrial diseases and is tightly linked to aging and neurodegenerative disorders such as Parkinsonandapos s and Alzheimerandapos sRecent discoveries support that mitochondrial dysfunction can be overcome to treat age related declineCyteGenandapos s hypothesis is that exercise induces the secretion of bloodborne proteins that act system ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. A Direct-Reading Liquid Crystal Based Formaldehyde Dosimeter for Personal Exposure Monitoring

    SBC: Platypus Technologies, LLC            Topic: NIEHS

    Platypus Technologies aims to advance the liquid crystalLCbased molecular analytic detection of formaldehyde that it established with SBIR Phase I support to complete the development and integrate its innovative LC based technology into product forms for rapid identification of formaldehyde emissions for short term and time weighted exposureTWAFormaldehyde is a known carcinogenand workplace exposu ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. A 3-month Release Naltrexone for Addiction Treatment

    SBC: Plumb Pharmaceuticals LLC            Topic: NIDA

    Opioid misuse is a world wide problemand it is increasingThe epidemic has shifted from a problem largely confined to urban areas to one that is both urban and ruralMaintenance therapy helps alleviate situational cravings and makes addiction therapy more effectivebut methadone clinics are largely confined to larger citiesbuprenorphine must be prescribed by physicians with a specific waiverand it ma ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government